Epstein Secrets

EPORTS 2Q '15 FINANCIAL RESULTS, Avalanche Bio Falls After Scrapping Plans for Ph.2b Study in 2H 2015-08-13 20:35:05.499 GMT By Jeremy R. Cooke (Bloomberg) -- Avalanche Biotechnologies said it won't initiate Phase 2b trial in 2H of 2015 after further analyses of previously reported Phase 2a data of AVA

niar To: "jeffrey E." <[email protected]> CC: Daniel Sabba , Ariane Dwyer Paul Morri Stewart Oldfield , Richard Kahn Subject: FW: (BFW) Avalanche Bio Falls After Scrapping Plans for Ph.2b Study [C] Date: Fri, 14 Aug 2015 14:32:36 +0000 Wine-Images: image003.jpg Classification: Confidential Jeffrey -

••••J Jill • •••• kvi *Used with permission of Bloomberg Finance LP Original Message From: Vahe Stepan

2:36 AM To: jeffrey E. ueevacation mail.corn CC: Daniel Sabb ; Ariane Dwye Paul Morris Stewart Oldfielt ; Richard Kahn [ Subject: FW: (BFW) Avalanche Bio Falls After Scrapping Plans for Ph. Classification: Confidential Jeffrey — posting you on AAVL. The stock is down —25% today to 510.289 on the back of ne

REPORTS 2Q'15 FINANCIAL RESULTS, Avalanche Bio Falls After Scrapping Plans for Ph.2b Study in 2H 2015-08-13 20:35:05.499 GMT By Jeremy R. Cooke (Bloomberg) -- Avalanche Biotechnologies said it won't initiate Phase 2b trial in 2H of 2015 after further analyses of previously reported Phase 2a data of AVA

EST. $0.4M BN 08/13 20:05 *AVALANCHE BIOTECHNOLOGIES, 2Q LOSS/SHR 38C BN 08/13 20:05 *AVALANCHE BIOTECHNOLOGIES, REPORTS 2Q'15 FINANCIAL RESULTS, Avalanche Bio Falls After Scrapping Plans for Ph.2b Study in 2H 2015-08-13 20:35:05.499 GMT By Jeremy R. Cooke (Bloomberg) -- Avalanche Biotechnologies said it won't